For disorders driven by a known genetic component, research understandably focuses on developing a drug targeting that genetic signature. When that works, the outcome benefits patients but the end ...
When Daniel Fischer cofounded Tevard Biosciences in 2017, he wasn’t trying to bet on the next hot RNA technology. His interest was more personal. His daughter Natasha has Dravet syndrome, a rare form ...
HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat hemophilia A. The Cambridge, Massachusetts-based biotech is closing “following ...
Alltrna is the latest in a growing number of startups with plans to develop therapies based on transfer RNA (tRNA), a family of RNA molecules that play a vital role in building proteins. The Cambridge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback